In randomized, global phase III trials, ceritinib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival vs. chemotherapy in patients with advanced ALK-positive NSCLC who were treatment-naïve (ASCEND-4 study) [6] or previously treated with crizotinib and one or two prior chemotherapy regimens (ASCEND-5 study) [7]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.